Cover Image
市場調查報告書

骨關節炎:開發平台分析

Osteoarthritis - Pipeline Review, H2 2016

出版商 Global Markets Direct 商品編碼 232841
出版日期 內容資訊 英文 281 Pages
訂單完成後即時交付
價格
Back to Top
骨關節炎:開發平台分析 Osteoarthritis - Pipeline Review, H2 2016
出版日期: 2016年08月24日 內容資訊: 英文 281 Pages
簡介

骨關節炎,是最常見的關節炎之一,是指軟骨,保護關節的材料損壞的慢性狀態。這成為骨頭互相摩擦的原因,導致僵硬、疼痛、關節動作低下。危險因子 有高齡,關節受傷,肥胖等。一般的症候,有關節的疼痛和僵硬,動了之後疼痛變得厲害,骨刺,吱嘎作響等。 治療為依據手、手腕、頭、背、膝、腰等損傷的關節狀態,進行藥物療法和運動。

本報告提供骨關節炎的治療藥開發平台的現狀及最新更新的各開發階段比較分析,企業和研究機關開發中的治療藥,治療藥的評估,後期階段及中止的計劃相關資訊等最新的新聞和發表。

簡介

  • 調查範圍
  • 骨關節炎 概要

治療藥的開發

  • 開發中產品;概要
  • 開發中產品;比較分析

企業開發中的治療藥

大學/機關研究中的治療藥

開發中產品概況

  • 後期階段的產品
  • 臨床階段的產品
  • 初期階段的產品

企業開發中的產品

大學/機關研究中的產品

治療藥開發作的企業

  • A. Menarini Industrie Farmaceutiche Riunite Srl
  • AbbVie Inc.
  • Abiogen Pharma S.p.A.
  • Ablynx NV
  • Achelios Therapeutics, Inc.
  • Addex Therapeutics Ltd
  • Akari Therapeutics, Plc
  • Amura Holdings Limited
  • Arcarios BV
  • 旭化成製藥
  • Asklepios BioPharmaceutical, Inc.
  • Astellas Pharma Inc.
  • Asterias Biotherapeutics, Inc.
  • Axsome Therapeutics, Inc.
  • Biopharm GmbH
  • Can-Fite BioPharma Ltd.
  • Cara Therapeutics, Inc.
  • Cardax Pharmaceuticals, Inc.
  • Cellceutix Corporation
  • Cellular Biomedicine Group, Inc.
  • Chong Kun Dang Pharmaceutical Corp.
  • Dong-A ST Co., Ltd.
  • Eli Lilly and Company
  • Evgen Pharma PLC
  • Galapagos NV
  • Genequine Biotherapeutics GmbH
  • GlaxoSmithKline Plc
  • IntelliCell BioSciences Inc.
  • Jeil Pharmaceutical Co., Ltd.
  • Jenrin Discovery, Inc.
  • K-Stemcell Co., Ltd.
  • Levolta Pharmaceuticals, Inc.
  • Medivir AB
  • Merck KGaA
  • Mesoblast Limited
  • Mor Research Application Ltd
  • NicOx S.A.
  • Nordic Bioscience A/S
  • Novartis AG
  • Ocata Therapeutics, Inc.
  • Omeros Corporation
  • 小野藥品工業
  • OrthoCyte Corporation
  • Osteologix Holdings Plc
  • Pfizer Inc.
  • Pharmalink AB
  • PLx Pharma Inc.
  • ProteoThera, Inc.
  • Regeneus Ltd
  • ReqMed Company, Ltd.
  • Sanofi
  • 生化學工業
  • Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd.
  • STELIS Biopharma Pvt. Ltd.
  • Stempeutics Research Private Limited
  • Symic Biomedical, Inc.
  • 武田藥品工業
  • TissueGene, Inc.
  • Upsher-Smith Laboratories, Inc.
  • Yooyoung Pharmaceutical Co., Ltd.
  • Yuhan Corporation
  • Yungjin Pharm. Co., Ltd.
  • Zimmer Biomet Holdings, Inc.
  • Zynerba Pharmaceuticals, Inc.

治療藥的評估

  • 單劑產品
  • 組合產品
  • 各標的
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

藥物簡介

  • (apocynin + paeonol)
  • (clodronate disodium + hyaluronic acid)
  • ABT-981
  • AlloJoin
  • AM-3701
  • AM-3876
  • Anatabine
  • 骨關節炎抑制劑
  • 骨關節炎 TGF-β1阻礙抗體
  • ARC-118
  • AS-001
  • ASP-7962
  • BNP-OA
  • BRM-421
  • CDX-085
  • celecoxib
  • CHND-1
  • CKD-941
  • clodronate disodium
  • CR-8357
  • CR-845
  • CRB-0017
  • CS-30MS02
  • DA-5202
  • DIS-BIO-EPS
  • DNX-314
  • 骨疾病、骨關節炎治療藥
  • 骨關節炎治療藥
  • 骨關節炎Renin Angiotensin抑制劑
  • 骨關節炎、骨折骨形成蛋白調整藥
  • 免疫學、代謝性疾病、肌肉骨骼障礙的PPAR-δ調整藥
  • duloxetine hydrochloride DR
  • fasitibant chloride
  • GLPG-1972
  • GQ-203
  • GQ-303
  • GSK-2394002
  • GZ-389988
  • JD-4000 Series
  • Kartogenin
  • KBP-056
  • ketoprofen
  • KM-278
  • LEVI-04
  • LH-023
  • LNA-043
  • MIV-711
  • 發炎性疾病、骨關節炎的單株抗體
  • 骨關節炎單株抗體抑制劑
  • MOR-106
  • MSBCAR-001
  • naproxcinod
  • NBS-101
  • NStride APS
  • OAX-1
  • ONO-4474
  • OTXCP-03
  • OTXCP-07
  • pentosan多硫酸鈉
  • 骨關節炎肽
  • piclidenoson
  • PL-1100
  • PRO-1
  • Progenza
  • 骨關節炎蛋白質
  • 骨關節炎、氣喘蛋白質
  • 類風濕性關節炎、骨關節炎蛋白質
  • 肥胖、骨關節炎、腎線維症、亞伯氏症候群 BMP-7活性蛋白質
  • PRX-167700
  • 骨關節炎組換肽
  • 骨關節炎、中樞神經IL-4/IL-10受體活性組換蛋白質
  • 骨關節炎IGF-1受體工作組換蛋白質
  • 骨質疏鬆症、骨關節炎PTH受體工作組換蛋白質
  • ReJoin
  • Salmon Calcitonin
  • SAR-396049
  • SB-061
  • SBL-005
  • SI-613
  • SM-04690
  • 變性性關節炎小分子
  • 骨關節炎小分子
  • 適合免疫學、血液學、神經疾病A2A促效劑
  • 骨關節炎MMP13抑制劑
  • 焦慮症、循環系統疾病、骨關節炎GPR22標靶藥物
  • 免疫學、代謝障礙、肌肉骨骼障礙小分子
  • 免疫學、肌肉骨骼障礙、代謝障礙小分子
  • 骨關節炎小分子
  • 免疫學、腸胃障礙、神經學、血液疾病TNFR1拮抗劑
  • 骨關節炎ADAMTS-5抑制劑
  • 骨關節炎補體系蛋白質抑制劑
  • 骨關節炎、骨質疏鬆症激化酵素抑制劑
  • 骨關節炎MMP-13抑制劑
  • sprifermin
  • 自體免疫疾病幹細胞療法
  • 中樞神經、CVS、皮膚疾病、免疫疾病n、代謝障礙幹細胞療法
  • 變性性關節炎幹細胞療法
  • 膝關節炎幹細胞療法
  • 多發性硬化症、類風濕性關節炎、骨關節炎、自閉症、肺支氣管發育不良、心臟衰竭、腦損傷性麻痺幹細胞療法
  • 骨關節炎幹細胞療法
  • 骨關節炎、真性糖尿病、急性肝功能衰竭心肺功能甦醒後疾病、神經退行性疾病幹細胞療法
  • Stempeucel
  • 關節炎基質細胞療法
  • Sulforadex
  • tonogenchoncel-L
  • TPX-100
  • TRBN-0224
  • UGP-302
  • VOLT-01
  • X-0002
  • XT-101
  • XT-150
  • YH-14619
  • YRA-1909
  • YY-1201
  • zoledronic acid
  • ZYN-002
  • ■最近的開發平台趨勢

暫停中的計劃

開發中止的產品

產品開發里程碑

  • 主要消息和新聞稿

附錄

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC8387IDB

Summary

Global Markets Direct's, 'Osteoarthritis - Pipeline Review, H2 2016', provides an overview of the Osteoarthritis pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Osteoarthritis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Osteoarthritis and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Osteoarthritis
  • The report reviews pipeline therapeutics for Osteoarthritis by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved Osteoarthritis therapeutics and enlists all their major and minor projects
  • The report assesses Osteoarthritis therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news related to pipeline therapeutics for Osteoarthritis

Reasons to buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for Osteoarthritis
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Osteoarthritis pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

  • Table of Contents
  • Introduction
  • Osteoarthritis Overview
  • Therapeutics Development
  • Osteoarthritis - Therapeutics under Development by Companies
  • Osteoarthritis - Therapeutics under Investigation by Universities/Institutes
  • Osteoarthritis - Pipeline Products Glance
  • Osteoarthritis - Products under Development by Companies
  • Osteoarthritis - Products under Investigation by Universities/Institutes
  • Osteoarthritis - Companies Involved in Therapeutics Development
  • Osteoarthritis - Therapeutics Assessment
  • Drug Profiles
  • Osteoarthritis - Dormant Projects
  • Osteoarthritis - Discontinued Products
  • Osteoarthritis - Product Development Milestones
  • Appendix

List of Tables

  • Number of Products under Development for Osteoarthritis, H2 2016
  • Number of Products under Development for Osteoarthritis - Comparative Analysis, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Number of Products under Development by Companies, H2 2016 (Contd..1)
  • Number of Products under Development by Companies, H2 2016 (Contd..2)
  • Number of Products under Development by Companies, H2 2016 (Contd..3)
  • Number of Products under Development by Companies, H2 2016 (Contd..4)
  • Number of Products under Investigation by Universities/Institutes, H2 2016
  • Comparative Analysis by Late Stage Development, H2 2016
  • Comparative Analysis by Clinical Stage Development, H2 2016
  • Comparative Analysis by Early Stage Development, H2 2016
  • Products under Development by Companies, H2 2016
  • Products under Development by Companies, H2 2016 (Contd..1)
  • Products under Development by Companies, H2 2016 (Contd..2)
  • Products under Development by Companies, H2 2016 (Contd..3)
  • Products under Development by Companies, H2 2016 (Contd..4)
  • Products under Development by Companies, H2 2016 (Contd..5)
  • Products under Investigation by Universities/Institutes, H2 2016
  • Osteoarthritis - Pipeline by A. Menarini Industrie Farmaceutiche Riunite Srl, H2 2016
  • Osteoarthritis - Pipeline by AbbVie Inc, H2 2016
  • Osteoarthritis - Pipeline by Abiogen Pharma S.p.A., H2 2016
  • Osteoarthritis - Pipeline by Ablynx NV, H2 2016
  • Osteoarthritis - Pipeline by Achelios Therapeutics, Inc., H2 2016
  • Osteoarthritis - Pipeline by Addex Therapeutics Ltd, H2 2016
  • Osteoarthritis - Pipeline by Amgen Inc., H2 2016
  • Osteoarthritis - Pipeline by Amura Holdings Limited, H2 2016
  • Osteoarthritis - Pipeline by Arcarios BV, H2 2016
  • Osteoarthritis - Pipeline by Asahi Kasei Pharma Corp., H2 2016
  • Osteoarthritis - Pipeline by Asklepios BioPharmaceutical, Inc., H2 2016
  • Osteoarthritis - Pipeline by Astellas Pharma Inc., H2 2016
  • Osteoarthritis - Pipeline by Asterias Biotherapeutics, Inc., H2 2016
  • Osteoarthritis - Pipeline by Biopharm GmbH, H2 2016
  • Osteoarthritis - Pipeline by Bone Therapeutics SA, H2 2016
  • Osteoarthritis - Pipeline by Can-Fite BioPharma Ltd., H2 2016
  • Osteoarthritis - Pipeline by Cardax Pharmaceuticals, Inc., H2 2016
  • Osteoarthritis - Pipeline by Cellceutix Corporation, H2 2016
  • Osteoarthritis - Pipeline by Cellular Biomedicine Group, Inc., H2 2016
  • Osteoarthritis - Pipeline by Evgen Pharma Plc, H2 2016
  • Osteoarthritis - Pipeline by Galapagos NV, H2 2016
  • Osteoarthritis - Pipeline by Genequine Biotherapeutics GmbH, H2 2016
  • Osteoarthritis - Pipeline by GlaxoSmithKline Plc, H2 2016
  • Osteoarthritis - Pipeline by IntelliCell BioSciences Inc., H2 2016
  • Osteoarthritis - Pipeline by Jeil Pharmaceutical Co., Ltd., H2 2016
  • Osteoarthritis - Pipeline by Jenrin Discovery, Inc., H2 2016
  • Osteoarthritis - Pipeline by K-Stemcell Co., Ltd., H2 2016
  • Osteoarthritis - Pipeline by Levolta Pharmaceuticals, Inc., H2 2016
  • Osteoarthritis - Pipeline by Medivir AB, H2 2016
  • Osteoarthritis - Pipeline by Merck KGaA, H2 2016
  • Osteoarthritis - Pipeline by Mesoblast Limited, H2 2016
  • Osteoarthritis - Pipeline by Mor Research Application Ltd, H2 2016
  • Osteoarthritis - Pipeline by NicOx S.A., H2 2016
  • Osteoarthritis - Pipeline by Nordic Bioscience A/S, H2 2016
  • Osteoarthritis - Pipeline by Novartis AG, H2 2016
  • Osteoarthritis - Pipeline by Omeros Corporation, H2 2016
  • Osteoarthritis - Pipeline by Ono Pharmaceutical Co., Ltd., H2 2016
  • Osteoarthritis - Pipeline by OrthoCyte Corporation, H2 2016
  • Osteoarthritis - Pipeline by Osteologix Holdings Plc., H2 2016
  • Osteoarthritis - Pipeline by Pfizer Inc., H2 2016
  • Osteoarthritis - Pipeline by Pharmalink AB, H2 2016
  • Osteoarthritis - Pipeline by Philogen S.p.A., H2 2016
  • Osteoarthritis - Pipeline by PLx Pharma Inc., H2 2016
  • Osteoarthritis - Pipeline by ProteoThera, Inc., H2 2016
  • Osteoarthritis - Pipeline by Regeneus Ltd, H2 2016
  • Osteoarthritis - Pipeline by Seikagaku Corporation, H2 2016
  • Osteoarthritis - Pipeline by STELIS Biopharma Pvt. Ltd., H2 2016
  • Osteoarthritis - Pipeline by Symic Biomedical, Inc., H2 2016
  • Osteoarthritis - Pipeline by Takeda Pharmaceutical Company Limited, H2 2016
  • Osteoarthritis - Pipeline by TissueGene, Inc., H2 2016
  • Osteoarthritis - Pipeline by Upsher-Smith Laboratories, Inc., H2 2016
  • Osteoarthritis - Pipeline by Yooyoung Pharmaceutical Co., Ltd., H2 2016
  • Osteoarthritis - Pipeline by Yuhan Corporation, H2 2016
  • Osteoarthritis - Pipeline by Yungjin Pharm. Co., Ltd., H2 2016
  • Osteoarthritis - Pipeline by Zimmer Biomet Holdings, Inc., H2 2016
  • Osteoarthritis - Pipeline by Zynerba Pharmaceuticals, Inc., H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Assessment by Combination Products, H2 2016
  • Number of Products by Stage and Target, H2 2016
  • Number of Products by Stage and Mechanism of Action, H2 2016
  • Number of Products by Stage and Route of Administration, H2 2016
  • Number of Products by Stage and Molecule Type, H2 2016
  • Osteoarthritis - Dormant Projects, H2 2016
  • Osteoarthritis - Dormant Projects (Contd..1), H2 2016
  • Osteoarthritis - Dormant Projects (Contd..2), H2 2016
  • Osteoarthritis - Dormant Projects (Contd..3), H2 2016
  • Osteoarthritis - Dormant Projects (Contd..4), H2 2016
  • Osteoarthritis - Dormant Projects (Contd..5), H2 2016
  • Osteoarthritis - Dormant Projects (Contd..6), H2 2016
  • Osteoarthritis - Dormant Projects (Contd..7), H2 2016
  • Osteoarthritis - Dormant Projects (Contd..8), H2 2016
  • Osteoarthritis - Dormant Projects (Contd..9), H2 2016
  • Osteoarthritis - Discontinued Products, H2 2016
  • Osteoarthritis - Discontinued Products (Contd..1), H2 2016

List of Figures

  • Number of Products under Development for Osteoarthritis, H2 2016
  • Number of Products under Development for Osteoarthritis - Comparative Analysis, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Number of Products under Investigation by Universities/Institutes, H2 2016
  • Comparative Analysis by Late Stage Development, H2 2016
  • Comparative Analysis by Clinical Stage Development, H2 2016
  • Comparative Analysis by Early Stage Products, H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Assessment by Combination Products, H2 2016
  • Number of Products by Top 10 Targets, H2 2016
  • Number of Products by Stage and Top 10 Targets, H2 2016
  • Number of Products by Top 10 Mechanism of Actions, H2 2016
  • Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016
  • Number of Products by Top 10 Routes of Administration, H2 2016
  • Number of Products by Stage and Top 10 Routes of Administration, H2 2016
  • Number of Products by Top 10 Molecule Types, H2 2016
  • Number of Products by Stage and Top 10 Molecule Types, H2 2016
Back to Top